Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders

Brandon M Huffman,Harshabad Singh,Lestat R Ali,Nora Horick,S Jennifer Wang,Megan T Hoffman,Katherine A Metayer,Shayla Murray,Alexandra Bird,Thomas A Abrams,Leah H Biller,Jennifer A Chan,Jeffrey A Meyerhardt,Nadine J McCleary,Wolfram Goessling,Anuj K Patel,Jeffrey S Wisch,Matthew B Yurgelun,Kent Mouw,Brendan Reardon,Eliezer M Van Allen,Jessica A Zerillo,Jeffrey W Clark,Aparna Parikh,Robert J Mayer,Benjamin Schlechter,Kimmie Ng,Sunil Kumar,Catherine Del Vecchio Fitz,Charlotte Kuperwasser,Glenn J Hanna,Andrew L Coveler,Douglas A Rubinson,Emma L Welsh,Kathleen Pfaff,Scott Rodig,Stephanie K Dougan,James M Cleary

DOI: https://doi.org/10.1136/jitc-2023-008436

IF: 12.469

2024-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed. Methods This multicenter phase II clinical trial ( NCT02919969 ) enrolled patients with metastatic or locally advanced incurable anal squamous cell carcinoma (n=32). Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint of the trial was objective response rate (ORR). Exploratory objectives included analysis of potential predictive biomarkers including assessment of tumor-associated immune cell populations with multichannel immunofluorescence and analysis of circulating tumor tissue modified viral-human papillomavirus DNA (TTMV-HPV DNA) using serially collected blood samples. To characterize the clinical features of long-term responders, we combined data from our prospective trial with a retrospective cohort of patients with anal cancer treated with anti-PD-1 immunotherapy (n=18). Results In the phase II study, the ORR to pembrolizumab monotherapy was 9.4% and the median progression-free survival was 2.2 months. Despite the high level of HPV positivity observed with circulating TTMV-HPV DNA testing, the majority of patients had low levels of tumor-associated CD8+PD-1+ T cells on pretreatment biopsy. Patients who benefited from pembrolizumab had decreasing TTMV-HPV DNA scores and a complete responder’s TTMV-HPV DNA became undetectable. Long-term pembrolizumab responses were observed in one patient from the trial (5.3 years) and three patients (2.5, 6, and 8 years) from the retrospective cohort. Long-term responders had HPV-positive tumors, lacked liver metastases, and achieved a radiological complete response. Conclusions Pembrolizumab has durable efficacy in a rare subset of anal cancers. However, despite persistence of HPV infection, indicated by circulating HPV DNA, most advanced anal cancers have low numbers of tumor-associated CD8+PD-1+ T cells and are resistant to pembrolizumab.

oncology,immunology